•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Defective Drugs
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Name of drug:

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

FDA orders warnings for Xolair

Feb 21, 2007 | UPI The U.S. Food and Drug Administration ordered Genentech Inc. to add a boxed warning to its asthmatic drug marketed as Xolair.

The FDA said the boxed warning should emphasize Xolair (omalizumab) might cause anaphylaxis, including trouble breathing, chest tightness, dizziness, fainting, itching and hives and swelling of the mouth and throat.

In addition, FDA ordered Genentech to revise the Xolair label and provide a medication guide for patients to strengthen the existing warning for anaphylaxis.

Xolair was approved in 2003 to treat adults and adolescents suffering moderate to severe persistent asthma and who have tested positive for a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled steroids.

Although anaphylaxis was reported in about one-in-1,000 patients during clinical trials, the FDA said continued reports prompted it to issue the Wednesday order.